CORT Key Statistics, Chart & Performance
The current stock price of CORT is 37 USD. In the past month the price decreased by -55.41%. In the past year, price decreased by -25.78%.
CORT Latest News, Press Relases and Analysis
CORT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 50.39 | 1.05T | ||
| JNJ | JOHNSON & JOHNSON | 19.99 | 499.91B | ||
| MRK | MERCK & CO. INC. | 12.33 | 269.55B | ||
| PFE | PFIZER INC | 7.9 | 143.73B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.65 | 115.47B | ||
| ZTS | ZOETIS INC | 19.82 | 55.38B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 10.07 | 23.89B | ||
| VTRS | VIATRIS INC | 5.35 | 14.35B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.79 | 11.35B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.60B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.73B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.06B |
Related stock screener links
About CORT
Company Profile
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company is headquartered in Redwood City, California and currently employs 500 full-time employees. The company went IPO on 2004-04-15. The firm is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The firm operates through the discovery, development and commercialization of the pharmaceutical products segment. The firm has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
Company Info
CORCEPT THERAPEUTICS INC
101 Redwood Shores Parkway
Redwood City CALIFORNIA 94025 US
CEO: Joseph K. Belanoff
Employees: 500
Phone: 16506888803
CORCEPT THERAPEUTICS INC / CORT FAQ
What does CORCEPT THERAPEUTICS INC do?
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company is headquartered in Redwood City, California and currently employs 500 full-time employees. The company went IPO on 2004-04-15. The firm is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The firm operates through the discovery, development and commercialization of the pharmaceutical products segment. The firm has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
Can you provide the latest stock price for CORCEPT THERAPEUTICS INC?
The current stock price of CORT is 37 USD. The price increased by 3.41% in the last trading session.
What is the dividend status of CORCEPT THERAPEUTICS INC?
CORT does not pay a dividend.
What is the ChartMill rating of CORCEPT THERAPEUTICS INC stock?
CORT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What is the GICS sector and industry of CORT stock?
CORCEPT THERAPEUTICS INC (CORT) operates in the Health Care sector and the Pharmaceuticals industry.
Would investing in CORCEPT THERAPEUTICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CORT.
Can you provide the upcoming earnings date for CORCEPT THERAPEUTICS INC?
CORCEPT THERAPEUTICS INC (CORT) will report earnings on 2026-02-24, after the market close.
CORT Technical Analysis
CORT Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to CORT. CORT gets an excellent profitability rating and is at the same time showing great financial health properties.
CORT Financial Highlights
Over the last trailing twelve months CORT reported a non-GAAP Earnings per Share(EPS) of 0.88. The EPS decreased by -30.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 14.32% | ||
| ROA | 12.88% | ||
| ROE | 16.79% | ||
| Debt/Equity | 0 |
CORT Forecast & Estimates
11 analysts have analysed CORT and the average price target is 129.72 USD. This implies a price increase of 250.61% is expected in the next year compared to the current price of 37.
For the next year, analysts expect an EPS growth of -20.21% and a revenue growth 18.44% for CORT